This commentary on the review by DA Saint in the current issue of the British Journal of Pharmacology focuses on the pathological role of late I Na in the heart, the evidence supporting inhibition of late I Na as a therapeutic target in ischaemic heart disease, and the therapeutic applications and challenges for development of new late I Na inhibitors. Recent reports from a large clinical outcome trial (MERLIN) of ranolazine, a drug known to inhibit late I Na , indicated that it was safe and reduced recurrent ischaemia and arrhythmic activity. In combination with other results indicating that inhibition of late I Na reduces ischaemia, myocardial Ca 2 þ overload, and electrical and mechanical dysfunction when late I Na is increased, the new clinical trial results suggest that reduction of cardiac late I Na is safe and therapeutically beneficial.
Introduction
The review by David Saint of the properties of the cardiac persistent late sodium current (I Na ) (Saint, 2007) , and of the potential therapeutic role(s) of drugs that inhibit this current, recognizes that late I Na may be increased in ischaemic and failing hearts and thus may be of general pathologic importance in heart disease. The discussion of blockers of late I Na in the review is timely, given the recent FDA approval of ranolazine for the treatment of chronic angina (the primary symptom of ischaemic heart disease) and the publication of results from a large clinical outcome trial with the drug Scirica et al., 2007) .
Why is enhanced late I Na pathologic?
Enhancement of late I Na is pathologic because it increases the intracellular concentration of Na þ , Na þ -Ca 2 þ exchange (NCX), Ca 2 þ entry into myocytes and duration of the myocardial action potential (AP). The increase of Ca 2 þ entry may be of sufficient magnitude to cause Ca 2 þ overloading with mechanical (e.g., impaired ventricular diastolic relaxation and reduction of diastolic coronary blood flow) and electrical (e.g., early and delayed afterdepolarizations: EADs and DADs) dysfunction . Enhancement of late I Na greatly increases Na þ entry during phase 2 of the ventricular AP (Makielski and Farley, 2006) . Because net outward current is small during phase 2, an enhanced late I Na reduces repolarization reserve and increases AP duration (APD). When phases 2 and 3 are prolonged, Ca 2 þ and Na þ channels may reopen, and the subsequent cation influx may lead to further APD prolongation and EADs. Spatial heterogeneity of prolongation of APD in the ventricle due to enhanced late I Na may set the stage for triggered and re-entrant arrhythmias. Enhanced late I Na disrupts Na þ and Ca 2 þ homeostasis. (Bers, 2001 ). Spontaneous release of Ca 2 þ from the sarcoplasmic reticulum during diastole increases NCX (Bers, 2001) . NCX is electrogenic, and its operation in the forward mode (3 Na þ in for 1 Ca 2 þ out) creates a transient inward current that can generate a DAD and triggered arrhythmic activity, as well as an aftercontraction (i.e., force production during diastole). Thus, both reverse (phases 1 and 2 of the AP) and forward (phases 2 and 3 and diastole) modes of NCX are enhanced subsequent to increases of late I Na and intracellular [Na þ ], although at different times during the cardiac cycle. The late I Na -enhanced oscillatory increases and decreases of the forward and reverse modes of the electrogenic NCX may become electrically destabilizing and cause formation of DADs. Elevation of the intracellular Ca 2 þ concentration secondary to an enhanced late I Na in ventricular myocytes impairs diastolic relaxation, that is, slows active relaxation of the ventricle (a negative lusitropic effect). Maintenance of contractile tension during a prolonged period of active ventricular relaxation increases myocardial oxygen consumption and reduces coronary blood flow during leftventricular (LV) isovolumic relaxation, when flow is normally at its peak. A reduction of diastolic coronary flow in a region of the myocardium with already reduced flow reserve only worsens the tenuous balance between oxygen supply and demand (see Figure 1 and Belardinelli et al., 2006 ). An increase of late I Na exacerbates the situation by facilitating AP prolongation, EADs and DADs. These acute electrical events are associated with increases in the cytosolic Ca 2 þ concentration, force production and delayed or reduced diastolic relaxation that further increase oxygen demand while concurrently reducing diastolic blood flow and myocardial oxygen supply. Thus, increases of late I Na and intracellular Ca 2 þ worsen LV function. Furthermore, although the role of late I Na in chronic calcium overloading is unknown, late I Na is reported to be increased in myocytes from failing hearts and from post-infarction remodeled myocardium (Huang et al., 2001; Undrovinas et al., 2006) . Heart failure appears to be a condition of chronic Ca 2 þ overloading that is associated with down-regulation of I Ca,L , increased NCX, prolongation of APD, decreased contractility and a proarrhythmic state (Bers, 2001 ).
Regional differences in the magnitude of late I Na in ventricular myocardium have been reported, and augmentation of these differences is proarrhythmic (Antzelevitch et al., 1999; Antzelevitch and Belardinelli, 2006) . In ischaemic and structurally abnormal hearts, it is doubtful that increases of late I Na and cellular Ca 2 þ overloading occur simultaneously and equally throughout the ventricle. Consequently, cell-tocell and regional dispersion of increases of late I Na and Na þ -induced Ca 2 þ overloading during ischaemia may lead to focal regions of EAD and DAD formation that increase the dispersion of ventricular repolarization. These events alter the conduction and chronology of ventricular electrical (and mechanical) activity, facilitate triggered and re-entrant arrhythmic activity, prolong the time needed for relaxation of systolic contraction and reduce contractile efficiency and diastolic blood flow (oxygenation) in the myocardium. Much evidence suggests that late I Na is enhanced in ischaemia, although quantization of late I Na in an intact, blood-perfused heart during ischaemia cannot be done. Myocardial-cell Na þ content increases during ischaemia (Bers, 2001 ). Myocardial-cell Ca 2 þ overload and dysfunction caused by ischaemia and reperfusion can be prevented by blockade of membrane Na þ channels or cardiac-specific ablation of NCX, thus implicating increased Na þ entry into cells as a proximate cause of Ca 2 þ overload . Hypoxia is known to impair inactivation of Na þ channels and increase late I Na (Saint, 2006) . Tissue hypoxia and reperfusion of ischaemic myocardium are reported to generate metabolites (e.g., palmitoyl-L-carnitine and lysophosphatidylcholine) and reactive oxygen/nitrogen species (e.g., hydrogen peroxide and nitric oxide) that increase late I Na in ventricular myocytes.
The mechanism of action of ranolazine to reduce electrical and mechanical dysfunction of the ischaemic myocardium Ranolazine, at concentrations within its therapeutic range (p10 mM), significantly reduces late I Na and reverses or prevents the consequences of increase of late I Na . Ranolazine reduces late I Na in mouse myocytes in which late I Na is enhanced due to expression of the long-QT syndrome 3 mutant sodium channel, DKPQ (Fredj et al., 2006) , in ventricular myocytes isolated from normal dogs and from dogs with heart failure (Undrovinas et al., 2006) , in guinea pig isolated ventricular myocytes exposed to anemone toxin-II or hydrogen peroxide (H 2 O 2 ) (Song et al., 2004 (Song et al., , 2006 and in HEK293 cells expressing human Na V 1.5 channels (Rajamani et al., 2007) . The range of values of IC 50 (potency) is 5.9-15 mM for ranolazine to reduce late I Na in various preparations. Ranolazine (1-10 mM) reduced APD and temporal dispersion of APD, and abolished EADs of guinea pig isolated ventricular myocytes in the presence of either anemone toxin-II or H 2 O 2 , both of which increase late I Na (Song et al., 2004 (Song et al., , 2006 , thus supporting the concept that reduction of an increased late I Na is anti-arrhythmic. Ranolazine (5-20 mM) reversibly and significantly shortened the APD of myocytes isolated from dogs with heart failure, in which late I Na is increased, and reduced variability of APD overload caused by anemone toxin-II or ischaemia/reperfusion in rat isolated hearts, and it enhanced recovery of postischaemic LV function, coronary flow and coronary vascular conductance . As expected, ranolazine had no effect on intracellular diastolic Ca 2 þ concentration, Ca 2 þ transient amplitude, LV function, coronary flow or coronary vascular conductance during aerobic conditions . Ranolazine-mediated block of late I Na was significantly reduced by mutation of a single amino-acid residue (F1760A) in the putative local anaesthetic binding site of the cardiac Na þ channel Na V 1.5 (Fredj et al., 2006) .
Thus, a putative site of 'binding' of ranolazine in the cardiac Na þ channel has been identified. In sum, the above findings strongly suggest that ranolazine alters the pathophysiology associated with Na þ -dependent Ca þ 2 overloading in myocardium by inhibiting late I Na .
The anti-ischaemic effects of ranolazine occur in the absence of haemodynamic changes. Although ranolazine has been reported to antagonize a 1 -and b-adrenergic antagonist activity in radioligand binding and in vitro tissue assays (Letienne et al., 2001) , at therapeutic concentrations (1-10 mM), it does not cause bradycardia or hypotension in animals (Wang et al., 1999) or in resting and exercising humans (Pepine and Wolff, 1999; Chaitman et al., 2004a, b; Rousseau et al., 2005) . In dogs that are awake, ranolazine at steady-state concentrations p18 mM did not cause significant slowing of heart rate or lowering of arterial blood pressure and did not affect coronary blood flow, coronary vascular resistance or LV contractility (CV Therapeutics, 2003) . These findings suggest that effects of ranolazine in vivo on haemodynamic parameters that are regulated by a 1 -or b 1 -adrenergic-mediated activity are not significant in normal dogs with intact autonomic nervous control mechanisms. Furthermore, ranolazine is cardioprotective in ischaemic protocols, wherein hearts are both electrically paced and perfused at constant rates, and in models using cytotoxic ischaemic metabolites , wherein selective b-adrenergic-receptor-blocking drugs are not cardioprotective. Thus, the data available to date do not indicate any contribution of the sympatholytic action of ranolazine to its anti-ischaemic and anti-anginal effects.
Inhibitions by ranolazine of ion currents other than late I Na do not appear to be responsible for the anti-ischaemic and anti-anginal effects of the drug. Inhibition of I Kr is likely responsible for the prolongation of the QT interval by ranolazine, but blockade of I Kr has not been shown to reduce ischaemic damage or angina. With other drugs, I Kr block has been associated with proarrhythmic activity, whereas ranolazine reduces both atrial and ventricular arrhythmic activity in humans . The significance of a reported inhibition by ranolazine of late I Ca (Antzelevitch et al., 2004) is unknown. Finally, ranolazine (1-10 mM) does not increase the duration of the QRS interval (i.e., does not slow the conduction of electrical activity), a finding consistent with its low potency to reduce peak I Na in the ventricle. The potencies (IC 50 values) of ranolazine to inhibit peak I Na in ventricular myocytes isolated from normal dogs and from dogs with heart failure were 294 and 244 mM, respectively (stimulation rate, 0.1 Hz; holding potential, À140 mV) (Undrovinas et al., 2006) . In the same study, the IC 50 for ranolazine to inhibit late I Na was 6.5 mM. These findings are consistent with the results of a large clinical outcome trial indicating that ranolazine does not increase mortality and reduces arrhythmic activity Scirica et al., 2007) .
Results of a recent 'proof-of-concept' study of patients with a long-QT syndrome 3 caused by a KPQ deletion in Na V 1.5 revealed that ranolazine (1.8-4 mM) significantly shortened the QTc interval and improved measures of the rate of diastolic relaxation of the left ventricle (data on file at CV Therapeutics Inc., Palo Alto, USA). In a different study of patients with a previous transmural myocardial infarction and with ejection fractions ranging from 13-55%, ranolazine improved diastolic function of the non-infarcted myocardium (Hayashida et al., 1994) . These results are consistent with the hypothesis that enhanced late I Na and its phenotypic manifestations are normalized by therapeutic concentrations of ranolazine in humans, and they provide compelling evidence that ranolazine inhibits late I Na of the human heart in vivo.
What are the potential therapeutic applications for an inhibitor of late I Na ?
Both preclinical experience with late I Na inhibitors and the clinical experience with ranolazine indicate that inhibition of late I Na improves function of the ischaemic myocardium. Cardiac angina, a symptom of myocardial ischaemia, is relieved by ranolazine (Chaitman et al., 2004a, b; Rousseau et al., 2005) . The anti-ischaemic effect of ranolazine, demonstrated in humans by an increased time to 1-mm STsegment depression during an exercise tolerance test (Pepine and Wolff, 1999; Rousseau et al., 2005) , and improved diastolic function (Hayashida et al., 1994) are the likely explanations for the action of ranolazine to alleviate angina in patients with ischaemic heart disease. The observation that late I Na is increased in myocytes from failing hearts of dog suggests that late I Na may be increased in heart failure, and thus heart failure may yet prove to be another indication for late I Na inhibitors (Maltsev et al., 2007) . Inhibition of late I Na reduces the prolonged ventricular APD (i.e., the QT interval), dispersion of repolarization, arrhythmic activity, Ca 2 þ loading of myocardial cells and diastolic dysfunction in heart failure (Undrovinas et al., 2006) . Diastolic heart function is improved in DKPQ long-QT syndrome 3 patients (as noted above), indicating that enhanced late I Na may contribute to, and reduction of late I Na may alleviate, diastolic dysfunction in some patients. Other potential therapeutic applications of late I Na inhibitors are neuronal and muscular disorders in which mutations in various noncardiac Na þ -channel isoforms (e.g., Na V 1.7 and Na V 1.4) are known to underlie the pathological phenotype, as in neuropathic pain, epilepsy, sudden infant death syndrome and muscular paralysis. The past 10 years have seen remarkable advancements in the identification of pathological effects of enhanced late I Na , causal mechanisms of Na þ channelopathies and disease states in which late I Na is enhanced. We speculate that increases of late I Na will be found to contribute to impairment of the functional status of excitable cells in many other situations. This is not unexpected, given that excessive late I Na may disrupt the homeostasis of Na þ -and Ca 2 þ -ion concentrations that maintain normal function of myocardial, neural, muscular and secretory cells. Current evidence of a role for reactive oxygen species to increase late I Na (Song et al., 2006) suggests that enhancement of late I Na may be a common phenomenon in processes such as ischaemia and aging.
What are the challenges in developing an inhibitor of late I Na ?
Understanding of the roles of late I Na in physiology and disease is still unfolding, and development of inhibitors of this current poses several challenges. Ion-channel-blocking drugs used for suppression of cardiac arrhythmias are often unselective for their given ion-channel target (e.g., amiodarone). Na þ -channel antagonists at present in therapeutic use (e.g., class I anti-arrhythmic agents), unlike many drugs (e.g., ligands of G-protein-coupled receptors), typically bind to their ion-channel targets with micromolar rather than nanomolar affinity. The goals of high potency, efficacy and selectivity that normally drive drug development may or may not be appropriate to find useful, safe blockers of late I Na . In the final analysis, inhibition of ion-channel function should perhaps be rather subtle and readily reversible, and the combination of ion-channel effects of a drug may determine its success or failure. When inhibiting cardiac late I Na , it is preferable to avoid inhibition of peak I Na , in the heart as well as in other excitable tissues. Drugs (e.g., flecainide, encainide) that inhibit peak I Na in the ventricle were associated with increased mortality in the Cardiac Arrhythmia Suppression Trial (Echt et al., 1991) . This finding suggests that late I Nablocking drugs must not alter Na þ channel opening and conductance during the AP upstroke (phase 0), to avoid slowing of impulse conduction and reduction of the wavelength of a re-entrant circuit. Reduction of peak I Na by ranolazine increases with increased frequency of stimulation and decreased membrane potential and appears to be tissue (atria vs ventricle; Burashnikov et al., 2007) , isoform (i.e., Na V 1.1-1.9) and mutation (e.g., late I Na s of various Na V 1.5-mutated channels are differentially responsive to ranolazine) dependent.
Inhibition of the HERG current I Kr is problematic, and many drugs, including Na þ -channel blockers, reduce this current. Reduction of I Kr is frequently associated with an increased incidence of torsades de pointes, a potentially fatal ventricular tachycardia. Reduction of late I Na offsets the reduction of repolarization reserve and the increase of APD and antagonizes the induction of EADs caused by I Kr blockers. Ranolazine reduces I Kr and prolongs, although modestly, the APD, but its effect is not rate (use) dependent, and it does not have proarrhythmic activity. The twofold greater potency of ranolazine to inhibit late I Na than to inhibit I Kr may contribute significantly to the anti-arrhythmic effects and absence of proarrhythmic effects of the drug. In post-myocardial infarction patients without ST-segment elevation but with a QTc interval greater than 450 ms, ranolazine significantly (Po0.001) reduced the incidence of ventricular tachycardia (X8 beats at X100 bpm, lasting less than 30 s) during 7 days of Holter monitoring by 47% compared with placebo . Lastly, how much reduction of cardiac late I Na is safe? At therapeutic concentrations, ranolazine reduces late I Na by about 50%. Would more be better? The answer may depend on the role of late I Na in normal cardiac function. For example, Purkinje fibres have a greater late I Na than other cells in the heart, and the duration of the Purkinje fibre AP is significantly shortened upon late I Na block. Excessive shortening of the Purkinje fibre APD may increase the risk of reentry. Similar concerns with blockade of physiological roles of late I Na in other tissues counsel caution in the development of potent drugs for incompletely understood targets such as late I Na . Nevertheless, the observation that ranolazine reduces ischaemia/angina, diastolic dysfunction and arrhythmic activity in a safe manner suggests that reduction of late I Na is therapeutically beneficial. However, scientific understanding of late I Na is in its infancy, and we remind ourselves that 'All scientific work is liable to be upset or modified by advancing knowledge' (Hill, 1965) .
